Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: A meta-analysis of individual patient data

Aging Clinical and Experimental Research

Volumn 17, Issue 2, 2005, Pages 150-156

  Adachi, Jonathan D ^a   Rizzoli, René ^b   Boonen, Steven ^c   Li, Zhengqing ^d   Meredith, Michael P ^d   Chesnut III, Charles H ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Individual patient data; Meta analysis; Osteoporosis; Risedronate; Survival analysis; Time to event data; Vertebral fracture

Indexed keywords

PLACEBO; RISEDRONIC ACID; DRUG DERIVATIVE; ETIDRONIC ACID;

ARTICLE; BONE DENSITY; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMUR NECK; HUMAN; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; VERTEBRA FRACTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL; SPINE FRACTURE;

BONE DENSITY; DOUBLE-BLIND METHOD; ETIDRONIC ACID; HUMANS; META-ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK REDUCTION BEHAVIOR; SPINAL FRACTURES;

EID: 23244465455     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324588     Document Type: Article

References (17)

1. Jeng GT, Scott JR, Burmeister LF. A comparison of meta-analytic results using literature vs individual patient data: paternal cell immunization for recurrent miscarriage. JAMA 1995; 274: 830-6.
2. Duchateau L, Pignon JP, Bijnens L, Bertin S, Bourhis J, Sylvester R. Individual patient-versus literature-based meta-analysis of survival data: time-to-event and event rate at a particular time can make a difference, an example based on head and neck cancer. Controlled Clin Trials 2001; 22: 538-47.
3. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341: 418-22.
4. Oxman AD, Clarke MJ, Stewart LA. From science to practice: meta-analyses using individual patient data are needed. JAMA 1995; 274: 845-55.
5. Eysenck HJ. Meta-analysis or best evidence synthesis? J Eval Clin Practice 1995; 1: 29-36.
6. Stewart LA, Clarke MJ, on behalf of the Cochrane Working Group. Practical methodology of meta-analysis (overviews) using updated individual patient data. Stat Med 1995; 14: 2057-79.
7. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999; 282: 1344-52.
8. Reginster J-Y, Minne HW, Sorensen OH, et al, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
9. FDA CDER. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Issued 4/1994. Available at: http://www.fda.gov/cder/guidance/osteo.pdf. Accessed November, 30, 2003.
10. McClung MR, Bensen W, Bolognese MA, et al. Risedronate increases BMD at the hip, spine, and radius in postmenopausal women with low bone mass. J Bone Miner Res 1997; 12 (Suppl. 1): S169 [Abstract].
11. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass. Results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 1895-900.
12. Hooper M, Ebeling P, Roberts A, et al. Risedronate prevents bone loss in early postmenopausal women. Calcif Tissue Int 1999; 64 (Suppl. 1): S69 [Abstract].
13. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
14. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, WHO, Geneva, 1994.
15. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991.
16. Black DM, Thompson ED, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 2000; 85: 4118-24.
17. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Rev 2002; 23: 517-23.